Physician profile
Denis A Boyle, JR.
NPI 1205920287
$942.10
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $311 · 2021: $171 · 2022: $92.81.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $277.33 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $152.88 | 2019-2021 | |
| Abbvie INC. | $141.26 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $131.02 | 2019-2021 | |
| Lilly USA, LLC | $81.97 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $49.61 | 2019-2020 | |
| Alkermes, INC. | $42.42 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.66 | 2020 | |
| Redhill Biopharma INC. | $14.57 | 2020 | |
| Allergan, INC. | $14.28 | 2020 | |
| Merck Sharp & Dohme LLC | $11.10 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denis Boyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.